Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	38.23B +173.4%
Revenue (ttm)	1.37B +12.0%
Net Income	870.39M +139.3%
EPS	1.39 +136.6%
Shares Out	618.09M
PE Ratio	44.46
Forward PE	111.46
Dividend	0.12 (0.19%)
Ex-Dividend Date	Nov 7, 2025

Volume	5,449,603
Average Volume	5,878,581
Open	61.61
Previous Close	61.86
Day's Range	59.13 - 61.61
52-Week Range	23.46 - 83.00
Beta	0.94
RSI	54.91
Earnings Date	Mar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,023
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.